Publications by authors named "Wojciech Cendrowski"
[Selected issues of immunomodulating treatment in multiple sclerosis].
Neurol Neurochir Pol
November 2004
Article Synopsis
- Placebo-controlled and open trials of immunomodulating drugs provide insights into treatment effects in relapsing-remitting and secondary progressive multiple sclerosis (RR MS, SP MS).
- Longer-term trials (4 years) of drugs like IFN beta-1b, IFN beta-1a, and glatiramer acetate showed modest benefits, with a notable decrease in relapse rates and increased progression-free patients in RR MS.
- In SP MS patients, while some trials indicated a marked increase in relapse-free percentages, the treatments did not significantly slow disease progression, suggesting mixed outcomes for different MS subtypes and a need for effective second-line therapies for non-responders.